Domestic initiatives: Aikawa cited recovery in customer spending, continued expansion of the dermatology customer base, establishment of what he described as the largest AGA hair loss treatment network in Japan , and expansion in orthopedics and fertility treatment . Management described a range of developments during fiscal 2025, including efforts to deepen the domestic platform and take early steps internationally. He also pointed to a steady quarterly recovery in average revenue per visit and said total ...

SBC Medical Group Holdings (NasdaqGM:SBC) Q4 2025 Earnings call March 27, 2026 08:30 AM ET Company ParticipantsHikaru Fukui - Head of Investor Relations and Chief Human Resources OfficerYoshiyuki Aikawa - CEO and ChairmanYuya Yoshida - Director, CFO, and COOHikaru FukuiResults briefing call. This meeting will be led by CEO Yoshiyuki Aikawa, Executive Vice President, CFO, COO, and AI Evangelist Yuya Yoshida, and myself, IR Manager Fukui, who will be moderating today. Thank you for your cooperation in advance ...

SBC Medical Group Holdings (NasdaqGM:SBC) Q4 2025 Earnings call March 27, 2026 08:30 AM ET Speaker2Results briefing call. This meeting will be led by CEO Yoshiyuki Aikawa, Executive Vice President, CFO, COO, and AI Evangelist Yuya Yoshida, and myself, IR Manager Fukui, who will be moderating today. Thank you for your cooperation in advance. Here is today's program. As a new initiative, we will begin with a 10-minute presentation by an AI avatar. Please rest assured that the content has been reviewed in adva ...

Investor Presentation 4Q and Full Year 2025 March 2026 Disclaimer This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company' ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 | Delaware | 88-1192288 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 200 Spectrum Center Dr. STE 300 Irvine, CA | 92618 | | (Address of principal executive offices) | (Zip Code) | Regis ...

Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year Exhibit 99.1 SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025 ...

SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results Share Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year IRVINE, Calif.--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical†or the "Company†), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial resu ...

Core Viewpoint - SBC Medical Group Holdings Incorporated is set to release its financial results for Q4 and the fiscal year ending December 31, 2025, on March 27, 2026, before the U.S. market opens [1] Group 1: Financial Results Announcement - The earnings conference call will take place on March 27, 2026, at 8:30 a.m. Eastern Time, where management will discuss financial performance, operational highlights, and key priorities for 2026 [2] - Registration for the conference call is required, and materials including the earnings release and archived webcast will be available on the Company's Investor Relations website [2] Group 2: Company Overview - SBC Medical operates as a Management Services Organization with a diverse portfolio in medical fields such as aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment, and ophthalmology [3] - The Company is expanding its global presence, particularly in the U.S. and Asia, through direct operations and medical tourism initiatives [3] - SBC Medical was listed on Nasdaq in September 2024 and included in the Russell 3000® Index in June 2025, reflecting its growth and market presence [3] - The Company aims to contribute to global well-being through medical innovation, providing high-quality medical services while enhancing its international reputation [3]

Group 1: Company Overview - SBC Medical Group Holdings Incorporated operates a diverse portfolio of franchise businesses across various medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology [6] - The company is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives [6] - SBC Medical was listed on Nasdaq in September 2024 and was included in the Russell 3000 Index in June 2025, indicating its growing prominence in the U.S. equity market [6][7] Group 2: Strategic Alliances and Initiatives - The alliance between SBC Medical and Daibi Medical Aesthetics aims to enhance understanding of China's medical environment and customer needs while increasing inbound customer visits to Shonan Beauty Clinic in Japan [1] - Physicians affiliated with Nasukai will collaborate with Daibi Medical Aesthetics to share knowledge on medical safety, clinic operations, and consultation practices, promoting professional exchange in aesthetic medicine between Japan and China [1] - Shonan Beauty Clinic has improved its inbound medical infrastructure, including the development of Chinese-language translation tools and the renewal of its official websites, to better serve overseas customers [3][4] Group 3: Market Trends and Growth Potential - The global medical tourism market is projected to grow at a compound annual growth rate (CAGR) of 23.0% from 2024 to 2032, reaching approximately USD 62.18 billion by 2032, reflecting increasing global interest in medical tourism [2] - Japanese aesthetic medicine is gaining recognition across Asia for its advanced technologies and safety standards, contributing to a steady increase in inbound customer visits to Shonan Beauty Clinic, which nearly tripled from approximately 600 customers in early 2024 to around 1,700 by the end of 2025 [3]

SBC Medical Group Holdings Conference Call Summary Company Overview - SBC Medical Group Holdings operates in the aesthetic medical industry, providing management services and products to cosmetic treatment centers. The company is headquartered in Irvine, California, and Tokyo, Japan, and trades on Nasdaq under the symbol SBC [1][3]. Key Points and Arguments Business Expansion and Strategy - SBC is the largest aesthetic medical group in Japan, with 258 franchise clinic locations and approximately 6.5 million annual customers [4]. - The company has diversified its offerings beyond aesthetic medicine to include orthopedics, ophthalmology, hair loss treatment, and infertility treatment, enhancing customer retention and broadening its market reach [4]. - SBC has recently signed a minority investment deal with OrangeTwist in the U.S. to facilitate global expansion, aiming to leverage successful practices from Japan while adapting to local markets [9][10]. Financial Performance - The company experienced a decline in sales due to business restructuring and adjustments to franchise fees, but signs of recovery are evident, particularly in average revenue per customer visit [5]. - The financial foundation remains strong, with a high EBITDA margin and sufficient cash reserves for strategic investments, including M&A activities [6][30]. Market Trends and Growth Projections - The U.S. aesthetic market is projected to grow to $71 billion by 2033, with a significant shift towards non-invasive treatments [11]. - SBC anticipates that international revenue, currently at 1%, could increase to over 20% in the next three to five years, primarily driven by M&A and partnerships [23][24]. Customer Demographics - There is a notable increase in young male customers seeking aesthetic treatments, indicating a shift in the customer mix and expanding market opportunities [26]. Operational and Regulatory Challenges - As SBC expands into the U.S. and Southeast Asia, it faces regulatory challenges, including compliance with HIPAA and local medical regulations. Partnering with established local players like OrangeTwist helps mitigate these risks [33][34]. Franchise Model - The franchise model in Japan operates under a non-profit medical corporation structure, with revenue generated from fixed and variable franchise fees based on services provided [28]. Medical Tourism - The company is seeing a rise in medical tourism, particularly from East Asian countries, due to high service quality and safety standards in Japanese clinics [32]. Additional Important Insights - SBC aims to be the top medical group in Japan by 2035 and globally by 2050, focusing on creating unique customer experiences and leveraging new technologies in wellness and aesthetics [15][16]. - The company is exploring opportunities to introduce high-class med spas in Japan, complementing its existing clinical offerings [14]. - SBC is committed to maintaining fiscal discipline while pursuing growth and partnerships, emphasizing the importance of strategic investments and operational efficiency [41]. This summary encapsulates the key points discussed during the SBC Medical Group Holdings conference call, highlighting the company's strategic direction, financial performance, market trends, and operational challenges.